Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4690511 | 0.86 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8013142 | 0.84 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31047777 | 0.83 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28458423 | 0.83 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27872882 | 0.82 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL26941528 | 0.82 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL622697 | 0.81 | POLB (0.40) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31540857 | 0.81 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4263538 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4284636 | 0.80 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626726-A2 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | Massachusetts Institute of Technology (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2970374-B1 | SOLID PHASE PEPTIDE SYNTHESIS | MASSACHUSETTS INST TECHNOLOGY (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180057525-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-03-01 | — | — | US | disclosed |
| US-20160031931-A1 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970374-A2 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | Massachusetts Institute of Technology (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014149387-A2 | SOLID PHASE PEPTIDE SYNTHESIS PROCESSES AND ASSOCIATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-5891640-A | USE OF THIS PEPTIDE, PARTICULARLY WHEN BIOTINYLATED IN THE FORM OF COMPLEXES OF STREPTAVIDIN-BIOTINYLATED PEPTIDES OR OF AVIDIN-BIOTINYLATED PEPTIDES, FOR THE IN VITRO DETERMINATION OF HIV-1-SPECIFIC ANTIBODIES | N.V. INNOGENETICS S.A. (BE) | 1999-04-06 | — | — | US | disclosed |
| US-5530124-A | Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| US-5112808-A | Promotes release of growth hormone | AMERICAN CYANAMID COMPANY (US) | 1992-05-12 | — | — | US | disclosed |